Join PER® September 15th for the New York Advanced Practice Collaborative Meeting! Directed toward NP/PAs, this meeting blends presentations on cutting-edge information with panel discussions to enhance learning.

FDA Approves Antiemetic

Wednesday, October 15, 2014
On October 10, 2014, an oral fixed-dose combination antiemetic (netupitant and palonosetron, marketed as Akynzeo by Helsinn/Eisai) was approved by the FDA for the prevention of chemotherapy-induced nausea and vomiting (CINV). The antiemetic is a combination of the tachykinin NK₁ receptor antagonist netupitant (300 mg dose) and the 5-HT₃ receptor antagonist palonosetron (0.5 mg dose).

The FDA noted that palonosetron, approved in 2008, prevents nausea and vomiting during the acute phase and netupitant, a new drug, prevents nausea and vomiting during both the acute and delayed phases.

The antiemetic’s effectiveness was confirmed in two clinical trials of 1,720 patients receiving chemotherapy. The trials compared the new combination against oral palonosetron, and found that the combination was more effective in preventing CINV. In the first trial, the percentage of patients who did not experience any vomiting or require rescue medication for nausea in the acute phase of CINV was 98.5% with the combination versus 89.7% with palonosetron alone. The percentage that did not experience delayed nausea and vomiting was 90.4% of the patients receiving the combination antiemetic versus 80.1% for those receiving only palonosetron,

Common adverse effects reported with the combination antiemetic in the clinical trials were headache, asthenia, fatigue, indigestion dyspepsia, and constipation. The FDA’s press announcement may be found at

Talk about this article with nurses and others in the oncology community in the General Discussions Oncology Nursing News discussion group.
Lisa Schulmeister, MN, RN, ACNS-BC, FAAN
Blog Info
Lisa Schulmeister, MN, RN, ACNS-BC, FAAN is an oncology nursing consultant and editor-in-chief of Oncology Nursing News.
Author Bio
Lisa Schulmeister, MN, RN, ACNS-BC, FAAN, is the Editor-in-Chief for OncLive Nursing. She is an oncology nursing consultant and adjunct assistant professor of nursing at Louisiana State Health Sciences Center in New Orleans, LA. She provides continuing nursing education to nurses across the Unites States, is active in several professional nursing organizations, and is intrigued by the many ways nurses use technology to communicate.
External Resources

MJH Associates
American Journal of Managed Care
MD Magazine
Pharmacy Times
Physicians' Education Resource
Specialty Pharmacy Times
OncNurse Resources

Continuing Education
Web Exclusives

About Us
Advisory Board
Contact Us
Privacy Policy
Terms & Conditions
Intellisphere, LLC
2 Clarke Drive
Suite 100
Cranbury, NJ 08512
P: 609-716-7777
F: 609-716-4747

Copyright OncNursing 2006-2018
Intellisphere, LLC. All Rights Reserved.